Stock NEU NEUREN PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

News Neuren Pharmaceuticals Limited

Equities

NEU

NZNEUE0001S8

Market Closed - Australian S.E.
Other stock markets
 07:10:13 28/06/2024 BST 		5-day change 1st Jan Change
21.27 AUD +3.15% Intraday chart for Neuren Pharmaceuticals Limited +6.35% -14.82%
05-28 Transcript : Neuren Pharmaceuticals Limited - Shareholder/Analyst Call
05-27 Neuren Phase 2 Trial Shows Significant Improvements in Pitt Hopkins Syndrome CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Transcript : Neuren Pharmaceuticals Limited - Shareholder/Analyst Call
Neuren Phase 2 Trial Shows Significant Improvements in Pitt Hopkins Syndrome
CI
Transcript : Neuren Pharmaceuticals Limited - Special Call
Neuren Pharmaceuticals Partner Acadia Pharmaceuticals Posts US DAYBUE Sales of $75.9 Million
MT
Neuren Pharmaceuticals Posts AU$243 Million Cash, Short-Term Investments
MT
Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada
MT
Weekly Top Ten News Stories - 15 March 2024
AQ
Neuren Pharmaceuticals Limited Provides Sales Guidance for the First Quarter and Full Year 2024
CI
Transcript : Neuren Pharmaceuticals Limited, Q4 2023 Earnings Call, Feb 29, 2024
Neuren Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Culper Research discloses short position in Acadia Pharma
RE
Neuren Pharmaceuticals Completes Recruitment for Phase Two Neurological Trial; Shares Fall 4%
MT
Neuren Pharmaceuticals Concludes Enrollment for Phase 2 Trial in Pitt Hopkins Syndrome
MT
Argenica Therapeutics Appoints Nonexecutive Chair
MT
Neuren Pharmaceuticals Posts Higher Q3 Net Sales in US for Rett Syndrome Treatment
MT
Fragile X Syndrome Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)
AQ
Fragile X Syndrome Pipeline, Clinical Trials and NDA Approvals 2023 (Updated)
AQ
Neuren Pharmaceuticals Limited(ASX:NEU) added to S&P/ASX 200 Index
CI
Neuren Pharmaceuticals Limited Reiterates Net Sales Guidance for the Third Quarter of 2023
CI
Neuren Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended June 30, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NEU Stock
  4. News Neuren Pharmaceuticals Limited